ACIP review of the hepatitis B birth dose vaccination remains a grave concern - Please read more here.

Site Search

You searched for "hepatitis D"

  • Phase 3 Clinical Trials Opening for Hepatitis Delta Patients

    Phase 3 clinical trials have been announced for two drugs, Lonafarnib and Myrcludex (Bulevirtide) for the treatment of hepatitis B and delta coinfection. Phase 3 studies compare new possible treatments to the current standard treatment, to see if it is more effective and/or safer than the current standard of care. Phase 3 studies are randomized control trials, which means that patients will be assigned to one of several different treatment groups. These studies usually evaluate the new treatment over a long period of time but special designations by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), such as Fast Track, Orphan Drug, Breakthrough Therapy Designations and PRIME eligibility status will speed up this process and bring these drugs to approval more quickly. Because the only currently approved treatment for hepatitis delta is pegylated interferon, which is often less than 30% effective, there is an unmet need for faster development of more treatment options. Phase 3 clinical trials for Lonafarnib are currently recruiting hepatitis B and delta coinfected patients in the United States. Ninety-two international trial site locations have also been announced and will take place in Belgium, Bulgaria, Canada, France, Germany, Greece, Israel, Italy, Republic of Moldova, New Zealand, Pakistan, Romania, Span, Switzerland, Taiwan, Turkey, United Kingdom and Vietnam. This clinical trial, run by Eiger Biopharmaceuticals, will test the new drug Lonafarnib in combination with other treatments. For more information about the study, visit www.D-LIVRstudy.com or clinicaltrials.gov. Bulevirtide, made by MYR-GmbH Pharmaceuticals, has also announced that its phase 3 clinical trials will be opening in 2019. Trial site locations have not been announced yet. For more information about this study, visit clinicaltrials.gov.Click here for more information on locating additional clinical trials. If you are considering joining a clinical trial,

    http://www.hepb.org/blog/phase-3-clinical-trials-opening-hepatitis-delta-patients/
  • Ask An Expert: Managing Hepatitis Delta During Pregnancy

        What is the standard treatment for hepatitis delta and how long is it taken?   Although there are no standard guidelines for the treatment of hepatitis delta, pegylated interferon has been shown to be effective for some patients. It is usually administered via weekly injections for 1 year or more and is able to cure roughly 15-40% depending on the length of time that treatment is administered. Although many patients see declines in their hepatitis delta virus levels, most do not maintain long-term control following the conclusion of treatment. Can pregnant hepatitis delta patients be treated with interferon?   Interferon has not been proven to be safe for administration during pregnancy and should not be administered. It may be harmful to the baby.   What is the best way to manage a hepatitis delta infection during pregnancy, if interferon cannot be used?   A liver specialist may continue to manage the hepatitis B infection during pregnancy through antiviral treatment. The American Association for the Study of Liver Diseases (AASLD) recommends antiviral treatment during the third trimester of pregnancy for women with high hepatitis B viral loads. How can hepatitis B and delta transmission be prevented to the baby?   Because a hepatitis B infection is required for someone to become infected with hepatitis delta, transmission from mother to child can be prevented with the hepatitis B vaccine. Centers for Disease Control and Prevention (CDC) guidelines recommend the first dose within 12 hours of birth, along with and a dose of HBIG (hepatitis B immunoglobulin), followed by the additional 2 vaccine shots; one at 1 month and the final one at 6 months old. The vaccine, along with HBIG and hepatitis B antiviral treatment (if necessary) greatly reduce the risk of transmission to the baby. In resource-limited countries, the World Health Organization (WHO) recommends the first dose of the hepatitis B vaccine within 24 hours of birth,

    https://www.hepb.org/blog/ask-expert-managing-hepatitis-delta-pregnancy/
  • World Hepatitis Day 2018: Why is Hepatitis B testing Important?

     You can help raise awareness and save lives… Tell us why you think hepatitis B testing is important? Globally, 292 million people are living with chronic hepatitis B. Only 10 percent are aware of their diagnosis. The theme for this year’s World Hepatitis Day is “Find the Missing Millions.” Help us raise awareness for World Hepatitis Day (July 28th, 2018) by telling the world why it is important to get tested for hepatitis B! Create an awareness message about hepatitis B by answering the prompt below.The Hepatitis B Foundation will compile video entries for a larger video that will be released on World Hepatitis Day, July 28, 2018. Who Can Enter? Anyone across the world! Here’s how to Enter: Record a short video or an audio clip of yourself (15 seconds or less) answering the prompt, “People should be tested for hepatitis B because ….” 2. Note: You may choose the audio option if you wish to remain anonymous. Film yourself answering the above question. Your face and/or your picture does not have to be in the video; however, we must be able to hear you. If you choose to record an audio clip you are welcome to send a picture from your country or something that represents you.  Keep your video no longer than 15 seconds! Send your video to us: By uploading your video to our Google form(You must have a gmail account) By messaging us your video on Facebook By uploading it to our Dropbox By emailing it to us at info@hepb.org You can also email the file using wetransfer. Please ensure that you send the email to info@hepb.org. When you send your video, please mention that you wish to participate in the World Hepatitis Day 2018 Campaign. Video Tips/Guidelines Your video must be 15 seconds or less Your video should be in English Note: If your video is recorded in a language other than English, please provide the English translation. If possible, provide a timed script with timings of phrases. Videos must be recorded in Landscape/horizontal mode.

    http://www.hepb.org/blog/world-hepatitis-day-2018-hepatitis-b-testing-important/
  • World Hepatitis Day: Because 4,000 Deaths a Day Is 4,000 Too Many

    By Christine Kukka The World Health Organization has designated July 28 as World Hepatitis Day, a day to work for global change to eliminate viral hepatitis and the suffering, death and discrimination that accompanies hepatitis B and C by 2030. From Asia to North America, on this day people around the world raise awareness about viral hepatitis and advocate for better access to treatment and prevention programs and more effective government action. Why? Because 4,000 deaths a day from viral hepatitis is 4,000 deaths too many. This action is critical, because for too long global leaders have made hepatitis a low priority. Viral hepatitis is a silent disease that causes no symptoms until it’s too late, and many believed the hepatitis B vaccine would simply make the infection go away. Instead, global health organizations focused on other diseases such as HIV/AIDS, tuberculosis and malaria. HIV especially benefited from unprecedented efforts and donated resources to enable diagnosis and prevention of transmission and to provide treatment at low cost. Today, we need the same effort and resources to eradicate viral hepatitis, which kill an estimated 1.4 million each year – more people  die from hepatitis annually than from HIV/AIDS and tuberculosis combined. For example, between 5 to 20 percent of the 1 billion people living in Sub-Saharan Africa have chronic hepatitis B Despite this prevalence, there are no widespread screening, education or prevention programs in Africa. The majority of people lucky enough to get screened and diagnosed for hepatitis B are often blood donors, because there are no public health clinics that provide screening for viral hepatitis. In Asia and Africa, even when pregnant women are diagnosed with hepatitis B, their newborns are often not given that critical, first vaccine dose within 12 hours of birth that would break the mother-to-child hepatitis B infection cycle. The birth dose of the hepatitis B vaccine is either too costly

    http://www.hepb.org/blog/world-hepatitis-day-4000-deaths-day-4000-many/
  • Celebrate World Hepatitis Day By Making Hepatitis B History

    Joan M. Block, Co-Founder and Executive Director By Joan M. Block, RN, BSN Executive Director and Co-Founder, Hepatitis B Foundation Tuesday, July 28, is World Hepatitis Day, which commemorates the birthday of Dr. Baruch S. Blumberg, who won the Nobel Prize in Medicine for identifying the hepatitis B virus and developing a vaccine to prevent it. This year also marks the 50th anniversary of the discovery of the hepatitis B virus – a discovery that has literally saved hundreds of millions of lives. Dr. Blumberg was also co-founder of the Hepatitis B Foundation, which was established in 1991 to help one single family. Today, we help millions. When the foundation began, the general public had no awareness about hepatitis B and affected individuals had nowhere to turn for information and support. Nonprofit organizations didn’t want to touch hepatitis B because it was perceived as an infectious disease due to undesirable lifestyle choices. Public health experts said the vaccine would wipe out hepatitis B in a generation so there was no need for a cure. Pharmaceutical companies didn’t see a profitable market for hepatitis B drugs, so they didn’t invest in discovery research and development. And, policy makers were uninterested because they weren’t hearing anything about the issue. Despite these challenges and obstacles, the foundation remained committed and persisted in fulfilling its research, outreach and advocacy mission. Over the years, it often felt like we were “the little engine that could” as we labored uphill to raise awareness, raise funds for our research and outreach programs, and raise hepatitis B as a national health priority in Washington. Our commitment was strengthened by Dr. Blumberg’s belief that hepatitis B could be eliminated in our lifetime. We believed it, too. The remarkable scientific and medical advances that have been made since his discovery are proof that hepatitis B is a problem that can be solved. Hepatitis B is a virus that

    http://www.hepb.org/blog/celebrate-world-hepatitis-day-by-making-hepatitis-b-history/
  • Hepatitis D Roundtable to Address Unmet Needs of Patients

    American Liver Foundation and Hepatitis B Foundation join forces with patients, medical providers and care partners in virtual two-day event  Fairfield, N.J., April 21, 2022—The American Liver Foundation (ALF) and Hepatitis B Foundation will join forces with key stakeholders concerned with identifying and addressing the unmet needs of people living with hepatitis D virus (HDV). The virtual Hepatitis D roundtable, to be held on April 21 and 22, will bring together medical experts, patients, and care partners in the hopes of finding solutions to some of the most vexing issues facing people living with HDV. HDV can only infect people who are also infected by the hepatitis B virus (HBV); infection can occur simultaneously (co-infection) or after infection with hep B (super-infection). HDV is often called a disease amplifier because it causes HBV to progress more rapidly resulting in cirrhosis or liver failure, making it more deadly. “There is a vast unmet need to diagnose, treat, and improve the lives of those living with hepatitis D,” Chari A. Cohen, DrPH, MPH, senior vice president of the Hepatitis B Foundation, said. "We're confident that the two days of robust discussion will yield valuable new insights and ideas for assisting people living with hepatitis D." In addition to addressing unmet needs of people living with HDV, the roundtable participants will seek to develop resources to better support and engage people in hepatitis D management, and open hepatitis D patient-doctor lines of communication to prioritize focus on the liver. “The link between people suffering from hepatitis B and hepatitis D and liver failure has not been well understood,” said Lorraine Stiehl, chief executive officer of American Liver Foundation. “That’s why we’re so pleased to partner with the Hepatitis B Foundation to help find solutions for patients and families struggling with these diseases and help raise awareness around the strong connection to liver failure.” The American Liver Foundation and Hepatitis B Foundation will jointly publish a report highlighting lessons learned from the roundtable, as a resource for people living with hepatitis D and their providers. For more about hepatitis D, visit Hepatitis Delta Connect, the website for the Hepatitis B Foundation’s program dedicated to HDV. Patients and caregivers are invited to join an American Liver Foundation free patient program, “Ask the Experts—Viral Hepatitis (HDV)” on May 19th at 2PM ET featuring leading physicians who will discuss findings and major discussion points from the Hepatitis D Roundtable. American Liver Foundation The American Liver Foundation is the nation’s largest non-profit organization focused solely on promoting liver health and disease prevention. The American Liver Foundation achieves its mission in the fight against liver disease by funding scientific research, education for medical professionals, advocacy, information and support programs for patients and their families as well as public awareness campaigns about liver wellness and disease prevention. The mission of the American Liver Foundation is to promote education, advocacy, support services and research for the prevention, treatment and cure of liver disease. For more information visit www.liverfoundation.org or call: 1 800 GO LIVER (800-465-4837). Follow us on Facebook Twitter LinkedIn YouTube  and Instagram HEP B FoundationAbout the Hepatitis B Foundation: We are the nation’s leading nonprofit organization solely dedicated to finding a cure for hepatitis B and improving the quality of life for those affected worldwide through research, education and patient advocacy. Founded in 1991, the Hepatitis B Foundation is based in Doylestown, Pa., with an office in Washington, D.C. To learn more, go to www.hepb.org, read our blog at hepb.org/blog, follow us on Twitter, Instagram and Facebook (@hepbfoundation) or call us at 215-489-4900. To donate, contact Jean Holmes at 215-489-4900 or jean.holmes@hepb.org.

    https://www.hepb.org/news-and-events/news-2/hepatitis-d-roundtable-to-address-unmet-needs-of-patients/
  • Journal Articles on Hepatitis B Research, Vaccination and Public Education

    Here is a selection of peer-reviewed journal articles and other scholarly publications co-authored by Hepatitis B Foundation public health researchers. Cohen, C., Evans, A.A., Block, T.M. (2023). Hepatitis Viruses: Hepatitis B and Hepatitis D. In: Kaslow, R.A., Stanberry, L.R., Powers, A.M. (eds) Viral Infections of Humans. Springer, New York, NY. [link] McMahon B, Cohen C, Brown RS, et al. Opportunities to Address Gaps in Early Detection and Improve Outcomes of Liver Cancer [published online ahead of print, 2023 May 5]. JNCI Cancer Spectrum 2023;7(3):pkad034. [link] Lim Y-S, WR Kim, Dieterich D, et al. Evidence for Benefits of Early Treatment Initiation for Chronic Hepatitis B 18April2023 Viruses 2023, 15(4), 997; [link] CDA Foundation; Coalition for Global Hepatitis Elimination, Hepatitis Australia, The Hepatitis Fund; Hepatitis B Foundation, Medicins Sans Frontieres Access Campaign, etc. (2022) An open letter to Gavi: hepatitis B birth dose vaccine can’t wait The Lancet: GastroenterolHepatol 5Dec2022 https://doi.org/10.1016/S2468-1253(22)00422-8 [link] Ha YP, Sun Y, Wilkinson J, Wang S, Chien L, Wu M, Wang E, Freeland C (2022) Implementation and outcomes of a remote hepatitis B screening program designed to overcome COVID-19 pandemic-related disruptions to community-based screenings for Asians in Greater Philadelphia: A descriptive study Health Science Reports    8August2022 https://doi.org/10.1002/hsr2.761 [link] Kheir OO, Freeland C, Abdo AE, Yousif MEM, Altayeb EA, Mekonnen HD (2022) Assessment of hepatitis B knowledge and awareness among the Sudanese population in Khartoum State Pan African Medical Journal  10.11604/pamj.2022.41.217.30390 [link] Ibrahim Y, Cohen C, Araojo R, Merenda C, Dykstra S, et al (2022) Attitudes towards clinical trial participation among people living with chronic hepatitis B. J Transl Sci. 2022; 8:1-10. Epub ahead of print. [link] Freeland C, Mendola L, Cheng V, Cohen C, Wallace J (2022) The unvirtuous cycle of discrimination affecting people with hepatitis B: a multi-country qualitative assessment of key-informant perspectives. Int J Equity in Health. 2022 May 31;21(1):77. [link] Matthews PC, Jack K, Wang S, Abbott J, Bryce K, Cheng B, Ghosh I, Story A, Chen J, Munoz C, Bell J, Riddell S, Goldring A, Goddard C, Moraras K, Cohen C, Brown K, Lazarus JV, Elsharkawy AM (2022) A call for advocacy and patient voice to eliminate hepatitis B virus infection. Lancet Gastroenterol Hepatol. 2022 Apr;7(4):282-285. [link] Silliman M, Alber M, Gib S, Gee M, Conover S, Chan C, Cohen C, Freeland C, Racho R (2022) Comparing lengths and inclusion of information in storytelling videos: Implications for hepatitis B education. PEC Innovation. Online ahead of print. [link] Freeland C, Mendola L, Cheng V, Cohen C, Wallace J (2022) The unvirtuous cycle of discrimination affecting people with hepatitis B: a multi-country qualitative assessment of key-informant perspectives. International Journal for Equity in Health [link]  Huynh TB, Nguyen DT, Vu N, Freeland C (2021) Development of health and safety training for Vietnamese American nail salon owners and workers medRxiv [link] C Freeland, M Kamischke, M Jackson, S Bodor, T Block, C Cohen, et al (2021). Common concerns, barriers to care, and the lived experience of individuals with hepatitis B: a qualitative study. BMC Public Health [link] Gish RG, Brosgart C, Lok A, Wong R, Block T, Cohen C, et al (2021) An Updated Assessment of Chronic Hepatitis B Prevalence among Foreign-Born Persons Living in the United States. Hepatology [link] Wang S, Cohen C, Tang A, Graham C (2021). Hepatitis B Virus Elimination in the U.S.: Time to Dismantle Barriers and Implement Solutions. Current Hepatology Solutions [link] Razavi H, Block, T, Cohen, C, et al (2020). The case for simplifying and using absolute targets for viral hepatitis elimination goals. Journal of Viral Hepatitis [link] Moraras K, Block J, Shiroma N, Cannizzo A, Cohen C (2020). Protecting the Rights of Health Care Students Living With Hepatitis B Under the Americans With Disabilities Act. Public Health Reports. [link] Tu T, Block JM, Wang S, Cohen C, Douglas MW (2020). The lived experience of chronic hepatitis B: a broader view of its impacts and why we need a cure. Viruses [link]  Freeland C, Bodor S, Perera U, Cohen C Barriers to Hepatitis B Screening and Prevention for African Immigrant Populations in the United States: A Qualitative Study. Viruses 2020:12(3), 305. [link] Alber JM, Cohen C, Racho R, Freeland C, Ghazvini S, Tolentino B, Almeida R, & Silliman M (2020) Exploring the impact of storytelling on storytellers in a hepatitis B health communication context. Patient Education & Counseling. [link] Alber JM, Cohen C, Bleakley A, Ghazvini S, Tolentino B, Almeida R, & Chance BL (2019). Comparing the effects of different story types and speakers in hepatitis B storytelling videos. Health Promotion Practice. [link] Alber JM, Cohen C, Nguyen G, Ghazani S, Tolentino B (2018). Exploring communication strategies for promoting hepatitis B prevention among young Asian American adults. Journal of Health Communication; 16:1-7. [link] Freeland C, Cohen C, Collier M (2018). Public health response to hepatitis B exposure: A case study on gaps and opportunities to improve postexposure care. Infectious Disease in Clinical Practice; 26(4):185-186. [link] Cohen, C, Alber, JM, Bleakley, A, Grossman, S, Freeland, C, Alarcon, K, Merchant, R (2018). Social media for hep B awareness: Young adult and community leader perspectives. Health Promotion Practice. Advanced online publication. [link] Alter H, Block T, Brown N, Brownstein A, Brosgart C, Chang K-M, Chen P-J, Chisari F, Cohen C, et al. (2018). A Research Agenda for Curing Chronic Hepatitis B Virus Infection. Hepatology; 67(3):1127-1131. [link] Block T, Alter H, Brown N, Brownstein A, Brosgart C, Chang K-M, Chen P-J, Cohen C, et al. (2017). Research priorities for the discovery of a cure for chronic hepatitis B: Report of a workshop. Antiviral Research; 150:93-100. [link] Cohen C, Evans AA, Huang P, London WT, Block J, Chen G (2016). Hepatitis B knowledge among key stakeholders in Haimen City, China: Implications for addressing chronic HBV infection. Hepatology, Medicine and Policy, 1(4):2-9. [link] Jorgensen C, Chen S, Carnes CA, Block J, Chen D, Caballero J, Moraras K, Cohen C (2016). “Know Hepatitis B:” A Multilingual Communications campaign Promoting Testing for Hepatitis B Among Asian Americans and Pacific Islanders. Public Health Reports, 2016 Supplement 2, v131: 35-40. [link] McMahon B, Block J, Block T, Cohen C, Evans AA, Hosangadi A, London WT, Sherman M, et. al. (2015). Hepatitis-Associated Liver Cancer: Gaps and Opportunities to Improve Care. JNCI J Natl Cancer Inst, 108(4):1-6. [link] Gish RD, Cohen CA, Block JM, Brosgart CL, Block TM, Clary R, Le LT, Ninburg MH, Sandt L, Kowdley KV (2015). Data supporting updating estimates of the prevalence of chronic hepatitis B and C in the United States. Hepatology, 62(5):1339-1341. [link] Evans AA, Cohen C, Huang P, Qian L, London WT, Block JM, Chen G (2015). Prevention of perinatal hepatitis B transmission in Haimen City, China: Results of a community public health initiative. Vaccine; epub ahead of print, pii: S0264-410X(15)00111-5. doi: 10.1016/j. Vaccine 2015.01.054. [link] Weerasinghe I, Bannister N, Huang V, Cohen C, Caballero J, Wang S (2015). The role of the patient-centered medical home in addressing hepatitis B perinatal transmission. AAPI Nexus, 12(1,2): 140-160. [link] Chen G, Block JM, Evans AA, Huang P, Cohen C (2014). Gateway to Care campaign: a public health initiative to reduce the burden of hepatitis B in Haimen City, China. BMC Public Health, 14:754-759. [link] Beckett GA, Block JM, Cohen C, McMahon BJ (2014). The role of primary care physician assistants in managing chronic hepatitis B. Journal of the American Association of Physician Assistants, 27(3):51-54. [link] Nguyen GT, Cohen C, Evans A, Bautista R (2014). Broadening the scope for national database sampling: a critical need. American Journal of Public Health, 104(2):e3. [link] Cohen C, Caballero J, Martin M, Weerasinghe I, Ninde M, Block J (2013). Eradication of Hepatitis B: A Nationwide Community Coalition Approach to Improving Vaccination, Screening, and Linkage to Care. Journal of Community Health, 38(5):799-804. [link] Evans AA, London WT, Gish RG, Cohen C, Block WT (2013). Chronic HBV Infection Outside Treatment Guidelines: Is Treatment Needed? Antiviral Therapy, 18(2):229-235. [link] Apuzzio J, Block JM, Cullison S, Cohen C, Leong SL, London WT, McHugh JA, Neubauer RL, Perrillo R, Squires R, Tarrant D, McMahon BJ (2012). Chronic Hepatitis B in Pregnancy: A Workshop Consensus Statement on Screening, Evaluation, and Management, Part 1. The Female Patient, 37(4):22-27. Apuzzio J, Block JM, Cullison S, Cohen C, Leong SL, London WT, McHugh JA, Neubauer RL, Perrillo R, Squires R, Tarrant D, McMahon BJ (2012). Chronic Hepatitis B in Pregnancy: A Workshop Consensus Statement on Screening, Evaluation, and Management, Part 2. The Female Patient, 37(5):30-34. McHugh JA, Cullison S, Apuzzio J, Block JM, Cohen C, Leong SL, London WT, McNellis RJ, Neubauer RL, Perrillo R, Squires R, Tarrant D, McMahon BJ (2011). Chronic hepatitis B infection: A workshop consensus statement and algorithm. Journal of Family Practice, Online Exclusive. 60(9):E1-E8. [link] Evans AA, Cohen C, London WT (2011). Hepatitis B Virus in the United States. Annals of Internal Medicine, 155(3):205. [link] Cohen C, McMahon BJ, Block JM, Brosgart CL, Gish RG, London WT, Block TM (2011). Is chronic hepatitis B being undertreated in the United States? Journal of Viral Hepatitis, 18:377-383. [link] Cohen C, Evans  A, London WT, Block J, Conti M, Block T (2008). Underestimation of chronic hepatitis B virus infection in the United States of America. Journal of Viral Hepatitis, 15(1):12–13. [link] Jessop A, Cohen C, Burke M, Conti M, Black M  (2004). Hepatitis support groups: Meeting the information and support needs of hepatitis patients. Journal of Gastroenterology Nursing, 27(4):163-169. [link] 

    https://www.hepb.org/news-and-events/reports/journal-articles-on-hepatitis-b-research-vaccination-and-public-education/
  • Joe's Story

    After being diagnosed with hepatitis B, Joe didn’t seek regular monitoring because his doctor didn’t provide information about what his diagnosis meant. Years later, he learned that his liver was inflamed, and that he was also infected with hepatitis delta – a serious coinfection of hepatitis B. Joe began to learn as much as he could about his coinfection, and after discovering that treatments were limited for hepatitis delta, he joined the only clinical trial available at the time. Although Joe had to discontinue the trial early, his health is now stable, and he is glad he has been able to contribute to important research. Even after his difficult journey, he is still hopeful that better treatments, and even a cure, are on the way.  

    https://www.hepb.org/research-and-programs/patient-story-telling-project/joes-story/
  • Testing and Diagnosis

    Who should be tested? While the American Association for the Study of Liver Diseases (AASLD) recommends that only high-risk groups be tested for hepatitis delta, the Hepatitis B Foundation recommends that all people living with hepatitis B get tested. Types of infections  There are two types of hepatitis delta infections: "superinfection" and "coinfection." Superinfections can occur when someone who already has chronic hepatitis B becomes infected with hepatitis delta - these types of infections are more common, and have a 70-90% chance of resulting in a chronic infection of both hepatitis B and delta. Coinfections can occur when someone becomes infected with hepatitis B and delta at the same time, and have less than a 5% chance of resulting in chronic infections. If available, testing for the HDV Antibody IgM can help determine if someone is experiencing a new hepatitis delta infection. Diagnosis A hepatitis delta diagnosis will require two tests: The hepatitis delta antibody (anti-HDV total) test and the hepatitis delta RNA (HDV RNA) test. The first step is performing the HDV antibody total (anti-HDV total) test. People who have recovered from or are currently infected with hepatitis delta will have antibodies. If the HDV antibody total test is positive, it should be followed by the HDV RNA (Qualitative or Quantitative) test to confirm an active infection. If this test is negative, a current infection is unlikely.  Ordering Testing In the past, availability and accuracy of testing for hepatitis delta has been limited. However, recent advancements have given more hope for this type of testing, which is now available from several labs within the U.S. and internationally: Quest Diagnostics (US) HDV Antibody, Total HDV Antibody IgM HDV RNA (Qualitative) HDV RNA (Quantitative) ARUP Laboratories (US) HDV Antibody Total HDV Antibody IgM HDV Antigen (ELISA) HDV RNA (Quantitative) BioAgilytix (US) Hepatitis D Antigen and IgM Antibody in Serum Mayo Clinic Laboratories (US) HDV Antibody Total Viracor (US) HDV Antibody Total HDV RNA (Qualitative) Centers for Disease Control and Prevention (CDC) (US & International) HDV Antibody Total HDV RNA Genotyping Disclaimer: This may not be a comprehensive list of all available labs offering hepatitis delta testing. Please note, if you are a patient in the U.S. and wish to be tested for hepatitis D, these tests must be ordered through a clinician.

    https://www.hepb.org/research-and-programs/hepdeltaconnect/testing-and-diagnosis/
  • World Hepatitis Day 2018

      You can help raise awareness and save lives… Tell us why you think hepatitis B testing is important!     Globally, 292 million people are living with chronic hepatitis B. Only 10 percent are aware of their diagnosis. Help us raise awareness for World Hepatitis Day (July 28th, 2018) by telling the world why it is important to get tested for hepatitis B! Create an awareness message about hepatitis B by answering the prompt below. The Hepatitis B Foundation will compile video entries for a larger video that will be released on World Hepatitis Day, July 28, 2018. Who Can Enter?: Anyone across the world! How to Enter! Record a short video or an audio clip of yourself (15 seconds or less) answering the prompt, “People should be tested for hepatitis B because ….” Note: You may choose the audio option if you wish to remain anonymous. Film yourself answering the above question. Your face and/or your picture does not have to be in the video; however, we must be able to hear you.  Keep your video no longer than 15 seconds Send your video to us: By uploading your video to our Google form By messaging us your video on Facebook By uploading it to our Dropbox By emailing it to us at info@hepb.org You can also email the file using wetransfer. Please ensure that you send the email to info@hepb.org When you send your video, please mention that you wish to participate in the World Hepatitis Day 2018 Campaign. Examples  WHD-Example-Image.mp4 WHD-Example.mp4 Video Tips/Guidelines Your video must be 15 seconds or less Your video should be in English Note: If your video is recorded in a language other than English, please provide the English translation. If possible, provide a timed script with timings of phrases. Videos must be recorded in Landscape/horizontal mode. Videos recorded in a Vertical format cannot be used. Record your video in a quiet area or with a microphone. Record your video in good lighting. Disclaimer By submitting a video to this campaign, participants give the Hepatitis B Foundation permission to use names (first names and/or initials will only be used), videos, voices, and likeness in the World Hepatitis Day campaign and promotion. The participant will waive any claims to royalty, right, or remuneration for such use. The Hepatitis B Foundation will not disclose any personal information obtained from participants (i.e., full names, email addresses, etc.) in the campaign to third parties and use the information for marketing and other purposes. For inspiration, visit our website, World Hepatitis Alliance’s Find the Missing Millions campaign, and CDC’s and Hep B United’s Know Hepatitis B campaign. Submission Period: You must submit your video by July 20, 2018 (Submission closes at 11:59 PM EST on 7/20/18) Have Questions? Please contact Kristine Alarcon at kristine.alarcon@hepb.org  

    https://www.hepb.org/news-and-events/worldhepatitisday2018/